Appendix 4E

• Full year revenue of $150.2 million, up 10% on prior year
• EBITDA of $35.2 million, up 8% on prior year
• Strong cash position of $80.4 million at 30 June 2025

Nanosonics Ltd, a leading provider of infection prevention solutions, has released its Appendix 4E for the full year ended 30 June 2025. The company reported a 10% increase in revenue to $150.2 million, driven by continued growth in its core trophon product line and the successful launch of new infection prevention technologies. EBITDA increased by 8% to $35.2 million, reflecting the company's focus on operational efficiency and cost management. Nanosonics maintained a strong cash position of $80.4 million as of 30 June 2025, providing a solid foundation for future growth and investment in research and development. The company's global expansion strategy, including the continued rollout of its products in key international markets, has been a significant contributor to the overall financial performance. Nanosonics remains committed to its mission of improving patient safety and reducing the risk of healthcare-associated infections through the provision of innovative infection prevention solutions.

Nanosonics is well-positioned for continued growth in the coming year, with a strong product pipeline, expanding global footprint, and a focus on driving operational excellence. The company remains committed to investing in research and development to further enhance its infection prevention capabilities and deliver innovative solutions to its customers.